Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
F083. Chronic Urticaria: What's New
Description
The discussion focuses on chronic spontaneous urticaria (CSU), emphasizing the need for dermatology to take a stronger role in managing this condition in the U.S. compared to Europe. The speaker elaborates on the biological mechanisms behind CSU, particularly the roles of mast cells and basophils in the inflammatory processes. He highlights the significance of IgE and autoimmune responses that bypass conventional antigen triggers, relying instead on autoantibodies. Recent findings suggest that interleukin-33 (IL-33) enhances histaminergic itch when combined with histamine, indicating a complex interplay of signaling pathways. Notably, the talk introduces MRGP RX-2, highlighting its potential in mast cell activation without prior IgE involvement, thus broadening the understanding of mast cell responses. The speaker also discusses emerging treatments targeting these pathways, including dupilumab and newer agents under development. The session concludes with a nod to innovative strategies, including bispecific antibodies aimed at selectively targeting activated mast cells, which represents a promising area for future research and therapeutic interventions in CSU.
View moreConclusions
- Chronic spontaneous urticaria (CSU) is characterized by persistent hives and itch, necessitating a clinical diagnosis.
- Mast cells and basophils are critical components in the pathophysiology of CSU, particularly through their activation and release of mediators like IL-33.
- In CSU, there is a dysregulation of immune responses involving autoallergens and IgE, with biological pathways driving mast cell degranulation.
- IL-33 plays a significant role in enhancing both the histaminergic itch and mast cell activation in CSU patients.
- Basophils are increasingly viewed as important players in urticaria due to their role in the IgE-mediated activation and potential for returning to skin homing.
- Therapeutic targeting of mast cells and basophils, including the use of monoclonal antibodies like omalizumab, shows promise in managing CSU and related conditions.
- New targets such as MRGPRX2 and histamine receptors indicate evolving strategies in the treatment of urticaria, with ongoing clinical trials.
- The interaction of neuroinflammation and itch in CSU suggests that treatment may need to address multiple pathways beyond just histamine modulation.
- Metz et al. NEJM 2025
- Trier & Ver Heul JACI 2023
- Abreu & Kim Immunol Allerg Clin 2021
- Wang et al. Cell 2021
- Auyeung et al. J Dermatol Treatment 2024
- Grekowitz et al. Br J Dermatol 2024